Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denintuzumab Mafodotin + RCHOP/RCHP in Frontline DLBCL or FL Grade 3b
NCT02855359Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Aug 2016
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of denintuzumab mafodotin in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Seagen Inc.. Started Aug 2016; status: terminated.
02
Drugs
denintuzumab mafodotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02855359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02855359.